Gurmukteshwar Singh

Dr. Gurmukteshwar Singh

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2022 in Kidney International
Verified
Journal Article
Closed access
BABenjamin Apple
Benjamin Apple
GSGino Sartori
Gino Sartori
BMBryn Moore
Bryn Moore
KCKiran Chintam
Kiran Chintam
GSGurmukteshwar Singh
Gurmukteshwar Singh
ACAlexander R. Chang
Alexander R. Chang

30 September 2021 in Kidney360
Verified
Journal Article
Closed access
PDF file
GSGurmukteshwar Singh
Gurmukteshwar Singh
YHYirui Hu
Yirui Hu
SJSteven Jacobs
Steven Jacobs
JBJason Brown
Jason Brown
JGJason George
Jason George
ACAlex Chang
Alex Chang
Key Points: Using innovative, patient-centered interventions, 68% of eligible high-risk patients with AKI were enrolled and all came to nephrology follow-up. Participation was associated with improvement in 30-day postdischarge rehospitalization and mortality, with similar 90-day trends. The interventions present a roadmap for improving enrollment in AKI randomized controlled trials and should be tested further. Background: Hospitalization-associated AKI is common and is associated with markedly increased mortality and morbidity. This prospective cohort study examined the feasibility and association of an AKI rehabilitation program with postdischarge outcomes. Methods: Adult patients hospitalized from September 1, 2019 to February 29, 2020 in a large health system in Pennsylvania with stage 2–3 AKI who were alive and not on dialysis or hospice at discharge were evaluated for enrollment. The intervention included patient education, case manager services, and expedited nephrology appointments starting within 1–3 weeks of discharge. We examined the association between AKI rehabilitation program participation and risks of rehospitalization or mortality in logistic regression analyses adjusting for comorbidities, discharge disposition, and sociodemographic and kidney parameters. Sensitivity analysis was performed using propensity score matching. Results: Among the high-risk patients with AKI who were evaluated, 77 of 183 were suitable for inclusion. Out of these, 52 (68%) patients were enrolled and compared with 400 contemporary, nonparticipant survivors of stage 2/3 AKI. Crude postdischarge rates of rehospitalization or death were lower for participants versus nonparticipants at 30 days (15% versus 34%; P=0.01) and at 90 days (31% versus 51%; P=0.01). After multivariable adjustment, participation in the AKI rehabilitation program was associated with lower risk of rehospitalization or mortality at 30 days (OR, 0.41; 95% CI, 0.16 to 0.93), with similar findings at 90 days (OR, 0.52; 95% CI, 0.25 to 1.05). Due to small sample size, propensity-matched analyses were limited. The participants’ rehospitalization or mortality was numerically lower but not statistically significant at 30 days (18% versus 31%; P=0.22) or at 90 days (47% versus 58%; P=0.4). Conclusions: The AKI rehabilitation program was feasible and potentially associated with improved 30-day rehospitalization or mortality. Our interventions present a roadmap to improve enrollment in future randomized trials.

8 January 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
MQMohammad Azfar Qureshi
Mohammad Azfar Qureshi
SMSerban Maierean
Serban Maierean
JCJohn H. Crabtree
John H. Crabtree
ACAlix Clarke
Alix Clarke
SASean Armstrong
Sean Armstrong
OROn Behalf Of The North American Peritoneal Dialysis Registry
On Behalf Of The North American Peritoneal Dialysis Registry
Background: This study investigated the association of intra-abdominal adhesions with the risk of peritoneal dialysis (PD) catheter complications. Methods: Individuals undergoing laparoscopic PD catheter insertion were prospectively enrolled from eight centers in Canada and the United States. Patients were grouped based on the presence of adhesions observed during catheter insertion. The primary outcome was the composite of PD never starting, termination of PD, or the need for an invasive procedure caused by flow restriction or abdominal pain. Results: Seven hundred and fifty-eight individuals were enrolled, of whom 201 (27%) had adhesions during laparoscopic PD catheter insertion. The risk of the primary outcome occurred in 35 (17%) in the adhesion group compared with 58 (10%) in the no adhesion group (adjusted HR, 1.64; 95% confidence interval [CI], 1.05 to 2.55) within 6 months of insertion. Lower abdominal or pelvic adhesions had an adjusted HR of 1.80 (95% CI, 1.09 to 2.98) compared with the no adhesion group. Invasive procedures were required in 26 (13%) and 47 (8%) of the adhesion and no adhesion groups, respectively (unadjusted HR, 1.60: 95% CI, 1.04 to 2.47) within 6 months of insertion. The adjusted odds ratio for adhesions for women was 1.65 (95% CI, 1.12 to 2.41), for body mass index per 5 kg/m 2 was 1.16 (95% CI, 1.003 to 1.34), and for prior abdominal surgery was 8.34 (95% CI, 5.5 to 12.34). Common abnormalities found during invasive procedures included PD catheter tip migration, occlusion of the lumen with fibrin, omental wrapping, adherence to the bowel, and the development of new adhesions. Conclusions: People with intra-abdominal adhesions undergoing PD catheter insertion were at higher risk for abdominal pain or flow restriction preventing PD from starting, PD termination, or requiring an invasive procedure. However, most patients, with or without adhesions, did not experience complications, and most complications did not lead to the termination of PD therapy. Podcast: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2024_11_15_CJASN2024Trainee2nd.mp3

28 August 2023 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CNChinedu Nwachukwu
Chinedu Nwachukwu
GSGurmukteshwar Singh
Gurmukteshwar Singh
BMBryn Moore
Bryn Moore
NSNatasha T. Strande
Natasha T. Strande
IBIon D. Bucaloiu
Ion D. Bucaloiu
ACAlex Chang
Alex Chang

27 June 2024 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
SPSunny Parmar
Sunny Parmar
Yvonne Commodore-MensahYvonne Commodore-Mensah
Yvonne Commodore-Mensah
GSGurmukteshwar Singh
Gurmukteshwar Singh
KFKathryn Foti
Kathryn Foti
CHCheryl Himmelfarb
Cheryl Himmelfarb
IBIon Dan Bucaloiu
Ion Dan Bucaloiu
BACKGROUND: Self-measurement of blood pressure (SMBP) is endorsed by current guidelines for diagnosing and managing hypertension (HTN). We surveyed individuals in a rural healthcare system on practices and attitudes related to SMBP that could guide future practice. METHODS: Survey questions were sent via an online patient portal to a random sample of 56,275 patients with either BP > 140/90 mm Hg or cardiovascular care in the system. Questions addressed home blood pressure (BP) monitor ownership, use, willingness to purchase, desire to share data with providers, perceptions of patient education, and patient-centeredness of care. Multivariable logistic regression was used to examine patient characteristics associated with SMBP behaviors. RESULTS: The overall response rate was 12%, and 8.4% completed all questions. Most respondents, 60.9%, owned a BP monitor, while 51.5% reported checking their BP at home the month prior. Among device owners, 45.1% reported receiving instructions on SMBP technique, frequency, and reading interpretation. Only 29.2% reported sharing readings with providers in the last 6 months, whereas 57.9% said they would be willing to do so regularly. Older age, female sex, and higher income were associated with a higher likelihood of device ownership. Younger age, lower income, and Medicaid insurance were associated with a greater willingness to share SMBP results with providers regularly. CONCLUSIONS: While a significant proportion of respondents performed SMBP regularly, many reported insufficient education on SMBP, and few shared their home BP readings with providers. Patient-centered interventions and telemedicine-based care are opportunities that emerged in our survey that could enhance future HTN care.

26 March 2022 in Genes
Verified
Journal Article
Open access
PDF file
GSGurmukteshwar Singh
Gurmukteshwar Singh
RGReginald Gohh
Reginald Gohh
DCDinah Clark
Dinah Clark
KKKartik Kalra
Kartik Kalra
MDManoj Das
Manoj Das
PAPrince Mohan Anand
Prince Mohan Anand
Family history of kidney disease increases risk of end-stage kidney disease (ESKD) in donors. Pre-donation genetic testing is recommended in evaluation guidelines and regulatory policy. Collaborating across several institutions, we describe cases to illustrate the utility as well as practical issues in incorporating genetic testing in transplant protocols. Case 1 is from 2009, before pervasive genetic testing. A healthy 27-year-old Caucasian male had an uneventful donor evaluation for his mother, who had early onset ESKD of unclear cause. He participated in paired-exchange kidney donation, but developed progressive kidney disease and gout over the next 10 years. A uromodulin gene mutation (NM_003361.3(UMOD):c.377 G>A p.C126Y) was detected and kidney biopsy showed tubulointerstitial kidney disease. The patient subsequently required kidney transplantation himself. Case 2 was a 36-year-old African American female who had an uneventful kidney donor evaluation. She underwent gene panel-based testing to rule out ApolipoproteinL1 risk variants, for which was negative. Incidentally, a sickle-cell trait (NM_000518.5(HBB):c.20A>T p.Glu7Val) was noted, and she was declined for kidney donation. This led to significant patient anguish. Case 3 was a 26-year-old Caucasian female who underwent panel-based testing because the potential recipient, her cousin, carried a variant of uncertain significance in the hepatocyte nuclear factor-1-β (HNF1B) gene. While the potential donor did not harbor this variant, she was found to have a likely pathogenic variant in complement factor I (NM_000204.4(CFI):c.1311dup:p.Asp438Argfs*8), precluding kidney donation. Our cases emphasize that while genetic testing can be invaluable in donor evaluation, transplant centers should utilize detailed informed consent, develop care pathways for secondary genetic findings, and share experience to develop best practices around genetic testing in donors.